Nasdaq GlobeNewswire

Motif Bio Reports Year-End 2016 Financial Results

Del

NEW YORK, May 01, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB.LN), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced financial results for the year ended December 31, 2016.

"Motif Bio made significant progress in 2016 towards our goal of bringing our novel antibiotic candidate, iclaprim, to patients with serious and life-threatening infections. The announcement of positive Phase 3 topline results for iclaprim in REVIVE-1 was a major achievement for Motif Bio and we expect to announce the topline data from REVIVE-2, the second Phase 3 trial, in the second half of 2017," commented Graham Lumsden, CEO of Motif Bio plc. 

Recent Corporate Developments

  • Announced positive topline results for iclaprim in the REVIVE-1 Phase 3 study of acute bacterial skin and skin structure infections (ABSSSI)
  • Data from REVIVE-2, which uses an identical protocol to REVIVE-1 but has different trial centres, has more than 80% of the total patients enrolled, and data is expected in the second half of 2017
  • Achieved a NASDAQ listing
  • Closed a U.S. initial public offering and a concurrent European placement with aggregate net proceeds of $21.5 million, which brought the total raised by the Company to approximately $65 million 
  • Appointed Robert Dickey IV as Chief Financial Officer
  • Presented two posters at ID Week 2016. The first showed new data demonstrating that iclaprim is highly potent in vitro against bacterial strains associated with clinical Hospital Associated Bacterial Pneumonia (HABP) and Skin and Skin Structure Infections (SSSI) clinical isolates. The second poster described the potential benefits of an optimized 80mg fixed dose of iclaprim administered intravenously over 120 minutes, that is being used in the REVIVE Phase 3 clinical trials. Improvement by approximately 30% in the PK/PD parameters associated with efficacy, AUC/MIC and t/MIC, was seen compared to the previously studied weight based dose of 0.8 mg/kg.
  • Completed preparations for INSPIRE, a Phase 3 trial designed to study the safety and efficacy of iclaprim in patients with HABP, including ventilator associated bacterial pneumonia (VABP)
  • Completed additional research with clinicians and payers to understand how iclaprim may be able to address the unmet need in hospitalised ABSSSI patients with renal impairment with/without diabetes

Full Year 2016 Financial Results

  • For the full year, Motif Bio reported a net loss of $40.3 million, or $(0.35) per share (basic and diluted) compared to a net loss of $8.5 million, or $(0.14) per share (basic and diluted) during the same period in 2015.
  • Research and development (R&D) costs for 2016 were $34.8 million compared to $4.7 million during 2015. Higher R&D costs in 2016 were primarily attributable to the commencement of iclaprim clinical development. Clinical development expenses are a significant component of our research and development expenses and product candidates in later stage development generally have higher costs.
  • General and administrative expenses for 2016 were $4.9 million compared to $3.6 million during 2015. The increase is primarily due to the costs associated with the filing of a registration statement relating to the initial public offering in the U.S.; costs associated with being a public company in both the United Kingdom and the U.S.; and increases in the costs of outside professional services.
  • Cash and cash equivalents were $21.8 million as of December 31, 2016.
  • As of December 31, 2016, the Company had 195.7 million ordinary shares outstanding.

Motif Bio has filed its U.S. Annual Report on Form 20-F for the year ended December 31, 2016 with the US Securities and Exchange Commission ("SEC"). The Form 20-F is available to download, either from the Investors section of the Company website at www.motifbio.com, the SEC website at www.sec.gov or from the link below.

Click here to download the Form 20-F

About iclaprim
Iclaprim is a potential novel antibiotic, designed to be effective against bacteria that have developed resistance to other antibiotics, including trimethoprim. Iclaprim exhibits potent in vitro activity against Gram-positive clinical isolates of many genera of staphylococci, including methicillin sensitive Staphylococcus aureus (MSSA) and methicillin resistant Staphylococcus aureus (MRSA). The MIC90 of iclaprim was lower than most comparators including vancomycin and linezolid, standard of care therapies used in serious and life-threatening Gram-positive hospital infections. To date, iclaprim has been studied in over 1,000 patients and healthy volunteers. Iclaprim is administered intravenously at a fixed dose, with no dosage adjustment required in patients with renal impairment, or in obese patients. This may help reduce overall hospital treatment costs, especially in renally impaired patients.

About Motif Bio plc  www.motifbio.com Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), infections often caused by MRSA (methicillin resistant Staphylococcus aureus). Having completed the REVIVE-1 trial, patients are currently being enrolled and dosed in a second global Phase 3 clinical trial (REVIVE-2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2 is expected in the second half of 2017.

Forward-Looking Statements 
This press release contains forward-looking statements. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Motif Bio's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Motif Bio believes that these factors include, but are not limited to, (i) the timing, progress and the results of clinical trials for Motif Bio's product candidates, (ii) the timing, scope or likelihood of regulatory filings and approvals for Motif Bio's product candidates, (iii) Motif Bio's ability to successfully commercialize its product candidates, (iv) Motif Bio's ability to effectively market any product candidates that receive regulatory approval, (v) Motif Bio's commercialisation, marketing and manufacturing capabilities and strategy, (vi) Motif Bio's expectation regarding the safety and efficacy of its product candidates, (vii) the potential clinical utility and benefits of Motif Bio's product candidates, (viii) Motif Bio's ability to advance its product candidates through various stages of development, especially through pivotal safety and efficacy trials, and (ix) Motif Bio's estimates regarding the potential market opportunity for its product candidates, and (x) the factors discussed in the section entitled "Risk Factors" in Motif Bio plc's Annual Report on Form 20-F filed with the SEC on May 1, 2017, which is available on the SEC's web site, www.sec.gov. Motif Bio plc undertakes no obligation to update or revise any forward-looking statements.

"This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014 and has been released by Robert Dickey IV, Chief Financial Officer, on behalf of the Company."

For further information please contact:

Motif Bio plc info@motifbio.com
Graham Lumsden (Chief Executive Officer)  
Robert Dickey IV (Chief Financial Officer)  
   
Peel Hunt LLP (NOMAD & BROKER) + 44 (0)20 7418 8900
Dr Christopher Golden  
Oliver Jackson  
   
Northland Capital Partners Limited (BROKER) +44 (0)203 861 6625
Patrick Claridge/ David Hignell  
John Howes/ Rob Rees (Broking)  
   
Westwicke Partners 001 415-513-1284
Patricia L. Bank patti.bank@westwicke.com
   
Walbrook PR Ltd. (FINANCIAL PR & IR) +44 (0) 20 7933 8780 or motifbio@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Mike Wort Mob: +44 (0)7900 608 002
   
MC Services AG (EUROPEAN IR) +49 (0)89 210 2280
   
   

Motif Bio plc Selected Financial Data

 
        Year
    Year
    Year
 
        ended
    ended
    ended
 
        12/31/2016
    12/31/2015
    12/31/2014
 
          US $
      US $
      US $
 
  Continuing operations              
  General and administrative expenses     (4,912,150 )       (3,577,180 )       (1,096,116 )
  Research and development expenses     (34,794,815 )       (4,680,940 )      -   
  Gains on settlement of contract disputes     83,320         5,027         360,060  
  Operating loss         (39,623,645 )       (8,253,093 )       (736,056 )
                 
  Interest income         69,754         15,028         78  
  Interest expense         (383,259 )       (268,216 )       (449,036 )
  Net foreign exchange losses       (250,926 )       (9,644 )      -   
  Loss from revaluation of derivative liabilities     (135,939 )       -          -   
                 
  Loss before income taxes         (40,324,015 )       (8,515,925 )       (1,185,014 )
  Income tax         (287 )       (774 )       (876 )
                 
  Net loss for the year         (40,324,302 )       (8,516,699 )       (1,185,890 )
                 
  Total comprehensive loss for the year     (40,324,302 )       (8,516,699 )       (1,185,890 )
                 
  Net loss per share              
  Basic and diluted per share *   $   (0.35 )   $   (0.14 )   $   (0.03 )
  Weighted average number of ordinary  shares, basic and diluted     116,558,191       61,225,922       36,726,342  
 
  *   In accordance with IAS 33 "Earnings per share", shares are not diluted where the entity has reported a loss for the period.

    December 31, 2016     December 31, 2015  
    US $     US $  
         
ASSETS        
Non-current assets        
Intangible assets     6,195,748       6,195,748  
Total non-current assets     6,195,748       6,195,748  
         
Current assets        
Prepaid expenses and other receivables   401,064       167,657  
Cash      21,829,632       28,594,347  
Total current assets     22,230,696       28,762,004  
         
Total assets     28,426,444       34,957,752  
         
LIABILITIES        
Non-current liabilities        
Payable on completion of clinical trial   -        500,000  
Total non-current liabilities     -        500,000  
         
Current liabilities        
Trade and other payables     12,319,117       987,083  
Other interest-bearing loans and borrowings   -        3,747,961  
Derivative liability     5,798,058       -   
Payable on completion of clinical trial   500,000       -   
Total current liabilities     18,617,175       4,735,044  
         
Total liabilities     18,617,175       5,235,044  
         
Net assets     9,809,269       29,722,708  
         
EQUITY        
Share capital   2,728,199     1,645,291  
Share premium   57,348,694     38,534,280  
Group reorganization reserve     9,938,362       9,938,362  
Accumulated deficit     (60,205,986 )     (20,395,225 )
         
Total equity     9,809,269       29,722,708  
     



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Motif BioSciences Inc. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Two London ex-Bankers launch first UK regulated Digital Asset Trading Platform and Crypto exchange accessible to Institutional Investors16.7.2018 17:37Pressemelding

LONDON, July 16, 2018 (GLOBE NEWSWIRE) -- UK's first native crypto exchange platform is on its way to become a reality. Sovren Exchange, a venture founded by a team of London-based banking executives, has announced an Initial Coin Offering (ICO) to begin Q3 of this year. For their launch, Sovren (SVRN) is raising a maximum of 10 Million USD (combination of Equity Funding and its own Sovren Token) to create a hybrid order book and brokerage exchange platform that uses a trading engine supported by Artificial Intelligence (AI) and Robotic Process Automation (RPA). Sovren will have a fully compliant platform that will support trading in derivates, equities, commodities and securities. The platform will use intelligent automation to address liquidity challenges and a 3rd party custodial service for additional protection with a European Bank. Sovren is supporting trading between all major crypto assets and fiat currencies like pounds, euros, and dollars, aiming for same day service and low,

TANTALEX Announces Entering into An Agreement with Respect to the Acquisition of an Exploitation Permit for the Historical Manono-Kitotolo Mine Tailings16.7.2018 16:48Pressemelding

TORONTO and MUNICH, Germany, July 16, 2018 (GLOBE NEWSWIRE) -- TANTALEX Resources Corporation (CSE:TTX) (FSE:1T0) ("TANTALEX" or the "Corporation"), is pleased to announce that its 90% owned subsidiary Buckell SAS ("Buckell") has entered into an assignment agreement (the "Agreement") to acquire Mines d'Or Resources ("Minor") 65% participation in a joint venture entity to which will be transferred the PER 13698 (Permis Exploitation Rejets) ("PER 13698"). PER 13698 grants exclusive rights to mine the tailings of the historical Manono-Kitotolo mine for lithium, tin and tantalum. The new entity will be named Société des Tailings de Manono ("STM") and will be owned 65% by Buckell, 30% by La Congolaise D'Exploitation Minière ("La Cominière") and 5% by Minor. The closing of the contemplated transaction by Buckell is subject to various conditions and payments, namely, but not limited to, the successful transfer and registration of the PER 13698 in the name of the newly created entity STM with

2018 Farnborough Air Show Marks Debut of Bombardier New ATMOSPHÈRE Cabin16.7.2018 12:00Pressemelding

MONTRÉAL, July 16, 2018 (GLOBE NEWSWIRE) -- Bombardier Commercial Aircraft unveiled the interior of the first CRJ Series aircraft with the new ATMOSPHÈRE cabin design on the opening day of the Farnborough International Air Show in the United Kingdom. Bombardier showcased the new cabin alongside launch operator Delta Air Lines and supplier Zodiac Aerospace during its air show inauguration event. "Our product is evolving, and this signature cabin design represents the latest innovation to our very successful regional jet program," said Fred Cromer, President, Bombardier Commercial Aircraft. "This cabin design will add value to airlines, the feedback has already been very positive as demonstrated with the recent momentum we have gained in the market." The CRJ900 aircraft on static display at the airshow is painted in Delta Air Lines livery and fitted with the ATMOSPHÈRE cabin. Bombardier will also emphasize its presence at the airshow from July 16-20 with a display of a Q400 aircraft in t

Aviation Solutions Provider Hawker Pacific to Collaborate with Pratt Whitney Canada on Array of Engine Maintenance Services16.7.2018 11:00Pressemelding

Agreement covers most PWC engine models and Digital Engine Services in Asia Pacific and the Middle East FARNBOROUGH, England, July 16, 2018 (GLOBE NEWSWIRE) -- Pratt & Whitney Canada (P&WC), a subsidiary of United Technologies Corp. (NYSE:UTX), today announced it has signed an agreement with Hawker Pacific under which the two companies will work together in a number of areas to further enhance the delivery of customer services and solutions. The comprehensive agreement spans most P&WC engine models and diagnostics and prognostics products across all segments: business aviation, general aviation, offshore, utility, regional aviation and defense and security. "Our agreement with P&WC is a testament to our continued commitment to delivering world class services and support to customers in Asia Pacific and the Middle East," said Doug Park, COO, Hawker Pacific. "We are thrilled to be working closely with P&WC to further extend their world class service network and deliver exceptional value

Fortuna reports production of 2.3 million ounces of silver and 14,557 ounces of gold for the second quarter of 201816.7.2018 11:00Pressemelding

VANCOUVER, British Columbia, July 16, 2018 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE:FSM) (TSX:FVI) is pleased to report production results for the second quarter of 2018 from its two operating mines in Latin America, the San Jose Mine in Mexico and the Caylloma Mine in Peru. The Company produced 2.3 million ounces of silver and 14,557 ounces of gold plus base metal by-products. Silver and gold production for the first six months totaled 4.7 million ounces and 29,597 ounces respectively; being 13 percent and 20 percent above the Company's mid-year projection. Fortuna is on schedule to produce 8.3 million ounces of silver and 48.3 thousand ounces of gold or 11.4 million Ag Eq1 ounces in 2018 in accordance with our production guidance (see Fortuna news release dated January 17, 2018). Second Quarter Production Highlights Silver production of 2,321,315 ounces; 10 percent increase over Q2 2017 Gold production of 14,557 ounces; in line with Q2 2017 Lead production of 7,186,541 pou

YouGov poll reveals UK adults are seeking innovative, digital payment experiences from their banks16.7.2018 01:04Pressemelding

New research showcases a list of innovative ways we'd like better protection against fraud and a more active role in controlling our payment cards· Switching cards on and off for better fraud controls, quickly reactivating blocked cards and mobile app based self-service is the future London, UK, July 16, 2018 (GLOBE NEWSWIRE) -- UK adults are ready for real-time interaction with their banks. The results of a recent YouGov survey, on behalf of Ondot, revealed today that online security and fraud prevention comes top in what Brits think banks should guarantee, with 60% wanting 'peace of mind' when using cards online. The survey also discovered that consumers are keen to play a much more proactive role in managing their personal finances. New ways of managing their card services before, during and after a payment; how, when and where cards are used and the ability switch your card 'on' and 'off' to create extra vigilance against fraud - are all important to today's card user. The omnibus

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom